Epoetin alfa

Epoetin alfa
Clinical data
Pronunciation	/ɛˈpoʊ.ɪtɪn/
Trade names	Epogen
Biosimilars	epoetin alfa-epbx, Abseamed, Binocrit, Epoetin Alfa Hexal, Retacrit
AHFS/Drugs.com	Monograph
MedlinePlus	a692034
License data	US DailyMed: Epoetin alfa;
Routes of; administration	Intravenous, subcutaneous
ATC code	B03XA01 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); US: WARNINGRx-only; EU: Rx-only;
Identifiers
CAS Number	11096-26-7 ;
DrugBank	DB00016 ;
ChemSpider	none;
UNII	64FS3BFH5W;
KEGG	D03231;
ChEMBL	ChEMBL1201565 ;
Chemical and physical data
Formula	C815H1317N233O241S5
Molar mass	18396.19 g·mol−1
	(what is this?) (verify)

Epoetin alfa, sold under the brand name Epogen among others, is a human erythropoietin produced in cell culture using recombinant DNA technology.^[8]^[9] Epoetin alfa is an erythropoiesis-stimulating agent.^[8] It stimulates erythropoiesis (increasing red blood cell levels) and is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy. Epoetin alfa is developed by Amgen.^[8]

It is on the World Health Organization's List of Essential Medicines.^[10] It was approved for medical use in the European Union in August 2007,

^ Cite error: The named reference Abseamed EPAR was invoked but never defined (see the help page).
^ "Abseamed". Union Register of medicinal products. Retrieved 14 January 2021.
^ Cite error: The named reference Binocrit EPAR was invoked but never defined (see the help page).
^ Cite error: The named reference Epoetin Alfa Hexal EPAR was invoked but never defined (see the help page).
^ "Retacrit- epoetin alfa-epbx injection, solution". DailyMed. 29 January 2020.
^ "Retacrit- epoetin alfa-epbx injection, solution". DailyMed. 26 June 2024. Retrieved 25 July 2024.
^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
^ ^a ^b ^c ^d "Epogen- epoetin alfa solution". DailyMed. 25 July 2018.
^ Walsh G, Spada S (2005). "Epogen/Procrit". Directory of approved biopharmaceutical products. Boca Raton: CRC Press. pp. 39–41. ISBN 978-0-415-26368-9.
^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.